The Trump administration wants your input on whether marijuana should be reclassified under international law. The U.S. Food and Drug Administration officially began accepting online comments this week, according to a notice the FDA published on the Federal Register
It’s the first-ever review of marijuana’s classification — conducted by The United Nations World Health Organization — and it’s inviting the opinions from member nations like the U.S. Currently, marijuana is considered a Schedule I narcotic. That means cannabis is not available for formal prescriptions and there are restrictions in terms of conducting cannabis research. Last year, WHO’s Expert Committee on Drug Dependence said CBD, a non-psychoactive cannabis compound found to be have medical benefits, has a good safety profile.
“To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD,” the report reads.
The Trump administration will use the input to inform America’s position on the issue before it weighs in with the UN, the governing body that sets the standard drug policy for countries involved in their drug control treaties. You can voice your opinion at regulations.gov. Those who wish to participate have until April 23 to submit comments online about why the U.S. should support reclassifying marijuana. The short process allows respondents to attach supporting documentation.